Anktiva

man juggling in the street
Pharma

ImmunityBio shares tank despite ph. 3 win in first-line NMIBC

With a phase 3 win in front-line non-muscle invasive bladder cancer, ImmunityBio is heading to the FDA for a label expansion.
Donavyn Coffey Nov 10, 2026 3:06pm
FDA Building

FDA clears ImmunityBio’s Anktiva expansion after back-and-forth

Oct 14, 2026 5:17pm
SoonShiong

ImmunityBio responds to FDA warning letter with new protocols

Apr 6, 2026 3:10pm
FDA

ImmunityBio hit with FDA warning letter over Anktiva promotions

Mar 24, 2026 1:15pm
On target clinical trial success bullseye score

ImmunityBio's Anktiva hits the mark in bladder cancer subtype

Dec 17, 2025 9:35am
A series of dice with a bag on them illustrating cost cuts

ImmunityBio turns to layoffs after recent FDA nod for Anktiva

Sep 5, 2024 11:27am